Sangamo Therapeutics, Inc. (SGMO)
$0.07+16.67%Close
SELLCRISIS · day 35
Key stats
- Market cap
- $29M
- Beta
- 1.29
- P/E (TTM)
- -0.20
- 1W
- +0.00%
- 1M
- +0.00%
- vs SPY 1W
- -1.16%
- vs SPY 1M
- -2.99%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 35
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-
GROSS100
OP-319
NET-357
[VALUATION]
P/E TTM-0.20
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B1094.51
P/FCF-
EV/EBITDA-0.26
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO-
ND/EBITDA-
BETA1.29
Company news
FAQ
- What is LOPJLB’s current signal on SGMO?
- LOPJLB’s latest quantitative signal on Sangamo Therapeutics, Inc. (SGMO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SGMO in?
- Sangamo Therapeutics, Inc. (SGMO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Sangamo Therapeutics, Inc. (SGMO) do?
- Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fib…